Evidence map›Paper›PMID 36476549›Full record

ArticleInternal medicine (Tokyo, Japan)2023

A Patient with Severe Fever with Thrombocytopenia Syndrome, Activated Partial Thromboplastin Time Prolongation, and Transient Antiphospholipid Antibodies.

Yutaka Tsukamoto, Takashi Sugimoto, Masataka Umeda, Takeharu Kato, Yukari Hiura, Kouichi Morita, Koya Ariyoshi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yutaka TsukamotoDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Japan.
Takashi SugimotoDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Japan.
Masataka UmedaDepartment of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Takeharu KatoDepartment of Hematology, Nagasaki University Hospital, Japan.
Yukari HiuraDepartment of Dermatology, Hiura Hospital, Japan.
Kouichi MoritaDepartment of Virology, Institute of Tropical Medicine, Nagasaki University, Japan.
Koya AriyoshiDepartment of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Japan.
Nagasaki University · JPNagasaki University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A prolonged activated partial thromboplastin time (APTT) is observed in patients with severe fever with thrombocytopenia syndrome (SFTS) and is one of the risk factors for severe disease. The mechanism underlying a prolonged APTT is largely unknown. The presence of antiphospholipid (aPL) antibodies in various viral infections has been documented but never reported in a patient with SFTS. We herein report the first SFTS patient with APTT prolongation and concurrent transiently positive aPL antibodies (lupus anticoagulants and anticardiolipin antibodies) with no coagulation factor deficiency.

Indexed as

Antiphospholipid SyndromeBlood Coagulation DisordersSevere Fever with Thrombocytopenia SyndromeAntibodies, AntiphospholipidHumansLupus Coagulation InhibitorPartial Thromboplastin TimeAntibodies, AntiphospholipidLupus Coagulation Inhibitoractivated partial thromboplastin timeantiphospholipid antibodyAPTTlupus anticoagulantsevere fever with thrombocytopenia syndromeSFTS

Identifiers

PMID36476549
PMCPMC10400393
OpenAlexW4310768549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.